Autosomal dominant polycystic kidney disease (ADPKD)
Also known as: Autosomal dominant polycystic kidney disease, Kidney, Renal, Nephric, Nephron
Methodology & AI Transparency ⓘ
Autosomal dominant polycystic kidney disease (ADPKD) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within Chronic Kidney Disease & Electrolytes practice, Autosomal dominant polycystic kidney disease (ADPKD) (also termed Autosomal dominant polycystic kidney disease or Kidney) (ICD-10 Q61.3) is stratified through spot urine albumin-to-creatinine in Autosomal dominant polycystic kidney disease (ADPKD) (Q61.3: ratio), pairing targeted symptom control with longitudinal Serum Potassium, Bicarbonate in Autosomal dominant polycystic kidney disease (ADPKD) (Q61.3: & Phosphorus) surveillance.
- 2 Real-world patient consensus: Synonyms for Autosomal dominant polycystic kidney disease (ADPKD) (Q61.3): Autosomal dominant polycystic kidney disease, Kidney, Renal (Kidney & Renal).
- 3 Typical cash cost range: Clinicians assessing Autosomal dominant polycystic kidney disease (ADPKD) focus on tubulointerstitial fibrosis [Autosomal dominant polycystic kidney disease (ADPKD) Q61.3] and targeted history.
- 4 Top reported side effects / signs: Longitudinal Autosomal dominant polycystic kidney disease (ADPKD) monitoring tracks Urine Albumin-to-Creatinine Ratio in Autosomal dominant polycystic kidney disease (ADPKD) (Q61.3: (uACR)) toward < 15 mg/g (< 30 mg/g normal) (Q61.3).
Ask our AI Specialists anything about Autosomal dominant polycystic kidney disease (ADPKD)
What Is Autosomal dominant polycystic kidney disease (ADPKD)?
Within Chronic Kidney Disease & Electrolytes practice, Autosomal dominant polycystic kidney disease (ADPKD) (also termed Autosomal dominant polycystic kidney disease or Kidney) (ICD-10 Q61.3) is stratified through spot urine albumin-to-creatinine in Autosomal dominant polycystic kidney disease (ADPKD) (Q61.3: ratio), pairing targeted symptom control with longitudinal Serum Potassium, Bicarbonate in Autosomal dominant polycystic kidney disease (ADPKD) (Q61.3: & Phosphorus) surveillance.
Pathophysiology, Underlying Causes & Clinical Presentation
In Autosomal dominant polycystic kidney disease (ADPKD) (Q61.3), physiological disruption stems from tubulointerstitial fibrosis [Autosomal dominant polycystic kidney disease (ADPKD) Q61.3], informing Chronic Kidney Disease & Electrolytes protocols that track Serum Potassium, Bicarbonate in Autosomal dominant polycystic kidney disease (ADPKD) (Q61.3: & Phosphorus) (K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (Q61.3)).
Common Symptoms & Clinical Signs
- • Presentation of Autosomal dominant polycystic kidney disease (ADPKD) (Q61.3): asymptomatic decline in in Autosomal dominant polycystic kidney disease (ADPKD) (Q61.3: eGFR or persistent)
- • Secondary Autosomal dominant polycystic kidney disease (ADPKD) clinical sign: fluid retention in in Autosomal dominant polycystic kidney disease (ADPKD) (Q61.3: ankles, hands, or)
- • Symptom flares in Autosomal dominant polycystic kidney disease (ADPKD) correlating with Urine Albumin-to-Creatinine Ratio in Autosomal dominant polycystic kidney disease (ADPKD) (Q61.3: (uACR)) deviation outside < 15 mg/g (< 30 mg/g normal) (Q61.3)
- • Functional kidney & renal impact requiring spot urine albumin-to-creatinine in Autosomal dominant polycystic kidney disease (ADPKD) (Q61.3: ratio) evaluation (Q61.3)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Autosomal dominant polycystic kidney disease (ADPKD) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | Q61.3 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Chronic Kidney Disease & Electrolytes | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio in Autosomal dominant polycystic kidney disease (ADPKD) (Q61.3: (uACR)) | < 15 mg/g (< 30 mg/g normal) (Q61.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Potassium, Bicarbonate in Autosomal dominant polycystic kidney disease (ADPKD) (Q61.3: & Phosphorus) | K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (Q61.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: eGFR (Creatinine + in Autosomal dominant polycystic kidney disease (ADPKD) (Q61.3: Cystatin C)) | >= 90 mL/min/1.73m2 (Q61.3) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Autosomal dominant polycystic kidney disease (ADPKD)
Treatment selection for Autosomal dominant polycystic kidney disease (ADPKD) depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Autosomal dominant polycystic kidney disease (ADPKD))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Effect of telemedicine support for intraoperative anaesthesia care on: What a 35,302-Participant Study Found In this large randomised clinical trial, intraoperative telemedicine decision support using real-time alerts and case reviews had no impact on adverse postoperative outcomes. British journal of anaesthesia • 2025-03-15 • Phase III Randomized Trial | N = 35,302 | 90/100 | PMID 39753404 ↗ |
| Can This Approach Help? Inside the Latest Research on Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 These ITCs indicate that, in patients with C3G, pegcetacoplan is associated with greater reductions in proteinuria levels, and more patients achieved the composite kidney endpoint compared with iptacopan. Advances in therapy • 2026-08-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42138781 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Nefecon in Patients with IgA Nephropathy from Mainland Nefecon treatment for 9 months showed greater preservation of eGFR over 2 years compared with placebo. Kidney360 • 2024-12-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39724565 ↗ |
| Can This Approach Help? Inside the Latest Research on Tolvaptan how the body absorbs the medicine and how the medicine works in the Tolvaptan was associated with large increases in free water clearance and urine output. European journal of pediatrics • 2025-12-18 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41407907 ↗ |
| Can This Approach Help? Inside the Latest Research on Veverimer on serum bicarbonate and physical function in women with chronic kidney Veverimer was effective in treating metabolic acidosis in women with CKD, and significantly improved how they felt and functioned. BMC nephrology • 2022-02-25 • Phase III Randomized Trial | N = 77 | 88/100 | PMID 35216581 ↗ |
Autosomal dominant polycystic kidney disease (ADPKD) Patient Community & “People Like Me” Threads
Filter Autosomal dominant polycystic kidney disease (ADPKD) community threads and patient logs by age, biological sex, dosage, and treatment duration.